Compare ClearPoint Neuro Inc (CLPT) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs ING Groep NV — how do they compare? ClearPoint Neuro Inc trades at $14.92 (market cap $444.14M), while ING Groep NV trades at $35.34 (market cap $101.24B). The key difference: ING Groep NV is far larger — about 227.9× ClearPoint Neuro Inc's market cap, and ING Groep NV pays a 3.74% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | ING | |
|---|---|---|
Market Cap | $444.14M | $101.24B |
Sector | Health | Financials |
52-Week High | $29.60 | $35.92 |
52-Week Low | $8.66 | $23.66 |
Enterprise Value | $478.72M | — |
Dividend Yield | — | 3.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.21, up 6.12% today, amid mixed technical signals and challenging fundamentals. The company reported Q2 2026 revenue growth but missed earnings expectations with a loss of $0.38 per share, continuing a trend of negative profitability. Despite 100% analyst buy ratings, financial metrics show significant losses with a net income margin of -81.76% and negative cash flow from operations of $30 million projected for 2026.
The investment case hinges on regulatory progress and partnership developments in neurotechnology, but substantial execution risks and persistent losses present headwinds. While analyst consensus remains bullish on long-term potential, current financial performance suggests cautious optimism is warranted until profitability improves.
ING trades at $35.68, down slightly by 0.08% on the day, with a bullish technical signal from moving averages and a neutral oscillator reading. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.79 versus $0.75 expected, and raised its full-year revenue guidance. Analyst consensus is strongly positive with 10 buy ratings and no sell ratings out of 16 analysts.
The outlook for ING is favorable, supported by earnings momentum and strategic initiatives, though risks include negative cash flow trends and potential market volatility. The stock presents a value opportunity with a P/E of 13.37 and a net income margin of 28.34%, but investors should weigh the persistent cash flow deficits against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
